Lucas Moreno, Rebekah Weston, Cormac Owens, Dominique Valteau-Couanet, Marion Gambart, Victoria Castel, C Michel Zwaan, Karsten Nysom, Nicolas Gerber, Aurora Castellano, Genevieve Laureys, Ruth Ladenstein, Jochen Rössler, Guy Makin, Dermot Murphy, Bruce Morland, Sucheta Vaidya, Estelle Thebaud, Natasha van Eijkelenburg, Deborah A Tweddle, Giuseppe Barone, Julie Tandonnet, Nadege Corradini, Pascal Chastagner, Catherine Paillard, Francisco J Bautista, Soledad Gallego Melcon, Bram De Wilde, Lynley Marshall, Juliet Gray, Susan A Burchill, Gudrun Schleiermacher, Louis Chesler, Andrew Peet, Martin O Leach, Kieran McHugh, Roisin Hayes, Neil Jerome, Hubert Caron, Jennifer Laidler, Nicola Fenwick, Grace Holt, Veronica Moroz, Pamela Kearns, Simon Gates, Andrew D J Pearson, Keith Wheatley
PURPOSE: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B). MATERIALS AND METHODS: Patients age 1-21 years with RR-HRNB with adequate organ function and performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) with or without B...
January 8, 2024: Journal of Clinical Oncology